Guidelines for the Blood Transfusion Services

Updates

2025

http://www.transfusionguidelines.org/red-book/latest-updates

Updates to the Red Book

28 February	CN 04-2025	4.2: Staffing and training principles for donation sessions4.3: Clinical leadership at donor sessions4.7: Equipment and consumables4.9: References
24 January	CN 02-2025	7.5.7: Human Plasma for Fractionation, Cryoprecipitate Depleted, Leucocyte Depleted
2024		
07 October	CN 28-2024	5.10: Staffing and training principles for donation sessions 5.13: Clinical leadership at donor sessions Chapter 5. Appendix L. Serious Adverse Events of Donation (removed)

		5.13: Clinical leadership at donor sessionsChapter 5, Appendix I - Serious Adverse Events of Donation (removed)
17 May	CN 29-2024	7.5.6: Human Plasma for Fractionation, Leucocyte Depleted
18 April	CN 05-2024	Chapter 21: Tissue banking: tissue retrieval and processing Annexe 7: Requirements for the timing of testing for Hematopoietic Progenitor Cells (HPCs)
13 March	CN 03-2024	Chapter 2: Quality in blood and tissue establishments and hospital blood banks Chapter 6: Evaluation and manufacture of blood components

Chapter 7: Specifications for blood components
Annexe 3: Provisional Components
Annexe 4: Redundant Components

Annexe 5: Blood Components for Contingency Use

2023

11 December	CN 40-2023	 7.31: Irradiated components 9.2: Microbiology screening 9.3: Specific screening targets 9.4: Reinstatement of blood donors 9.7: Recommended standards for environmental monitoring (EM) of processing facilities
02 November	CN 39-2023	Annexe 7: Requirements for the timing of testing for HPCs
0=	CIT OU LOLO	, among the restaurant of the among of tooking for the co

04 September	CN 16-2023	Chapter 4: Premises and quality assurance at blood donor sessions Chapter 5: Collection of a blood or component donation Chapter 11: Reagent manufacture Chapter 12: Donation testing (red cell immunohaematology) Chapter 13: Patient testing (red cell immunohaematology) Chapter 14: Guidelines for the use of DNA/PCR techniques in Blood Establishments Chapter 15: Molecular typing for red cell antigens Chapter 16: HLA typing and HLA serology
		Chapter 16. HEA typing and HEA serology Chapter 17: Granulocyte immunology
		Chapter 18: Platelet immunology
		Chapter 22: Haemopoietic progenitor cells
		Annexe 7: Requirements for the timing of testing for HPCs
12 April	CN 22-2023	Annexe 3.5: Red Cells and Plasma, Leucocyte Depleted
13 February	CN 06-2023	Chapter 9: Microbiology tests for donors and donations: general specifications for laboratory test procedures
		Chapter 10: Investigation of suspected transfusion-transmitted infection Chapter 19: Tissue Banking: general principles
		Chapter 19. Tissue Banking: general principles Chapter 20: Tissue Banking: selection of donors
		Chapter 21: Tissue Banking: tissue retrieval and processing
		Annexe 6: Advanced Therapy Medicinal Products (ATMPs)
2022		
22 June	CN 33-2022	Chapter 8: Evaluation of novel blood components, production processes and blood packs: generic protocols
22 March	CN 09-2022	7.5.6: Human Plasma for Fractionation, Leucocyte Depleted
02 March	CN 10-2022	Annexe 4: Redundant Components - Convalescent Plasma
02 March	CN 11-2022	Annexe 3: Provisional Components - Whole blood, leucocyte depleted, for clinical studies
02 March	CN 12-2022	Annexe 3: Provisional Components - Cryoprecipitate pooled, leucocyte depleted, extended shelf life post-thaw
11 January	CN 44-2021	Annexe 5: Blood Components for Contingency Use
2021		
00 1	01140.0004	
22 June	<u>CN 18-2021</u>	Chapter 3: - Care and selection of whole blood and component donors (including donors of pre-deposit autologous blood)
12 January	CN 03-2021	Chapter 21: Tissue banking: tissue retrieval and processing
12 January	<u>UN US-2U21</u>	Chapter 21. Hoode ballning, tioode retrieval and processing
2020		
17 November	CN 66-2020	Annexe 3: Provisional Component - Convalescent Plasma (COVID-19), FFP, Leucocyte Depleted
17 November	CN 67-2020	Annexe 3: Provisional Component - Convalescent Plasma (COVID-19), FFP, for Neonates and Infants, Leucocyte Depleted

26 October	CN 35-2020	Annexe 3: Provisional Component - Whole Blood, Leucocyte Depleted for Clinical Studies
16 September	CN 47-2020	Annexe 5: Platelets, Apheresis, Leucocyte Depleted, at Reduced Dose as a Contingency
08 June	CN 32-2020	Annexe 3: Provisional Component - Red Cells and Plasma, Leucocyte Depleted
06 May	CN 23-2020	Chapter 7: Fresh Frozen Plasma for Neonates and Infants, Leucocyte Depleted
06 May	CN 24-2020	Chapter 7: Cryoprecipitate for Neonates and Infants, Leucocyte Depleted
06 May	CN 25-2020	Chapter 7: Fresh Frozen Plasma, Leucocyte Depleted
07 May	CN 27-2020	3.15: Blood Tests
21 April	CN 19-2020	Annexe 4: Redundant Components
21 April	CN 20-2020	Annexe 4: Redundant Components - Granulocytes, Apheresis
21 April	CN 21-2020	Annexe 5: Blood Components for Contingency Use
21 April	CN 22-2020	Annexe 5.1: Red Cells in Additive Solution, Leucocyte Depleted, Extended Shelf Life
2019		
26 November	CN 34-2020	Chapter 7: Platelets in Plasma and Additive Solution for Neonatal Use, Leucocyte Depleted
2017		
06 April	CN 10-2017	Chapter 7: Use of plasma from first time donors
27 January	CN 01-2017	Chapter 11: General guidelines for reagent red cell manufacture
27 January	CN 02-2017	Chapter 17 and 18 - Additional guidance re HNA and HPA antibody detection methods
2016		
15 August	CN 32-2016	Chapter 7: Red Cells, Thawed and Washed, Leucocyte Depleted
15 August	CN 33-2016	Chapter 7: Removal of red cells from a controlled temperature environment
15 August	CN 34-2016	Chapter 7: Removal of upper limit of pH from Platelet Components
21 June	CN 31-2016	Annexe 3: Trial Components
11 May	CN 23-2016	Chapter 21: Tissue banking: Tissue retrieval and processing
01 April	CN 16-2016	Chapter 7: Fresh Frozen Plasma, Leucocyte Depleted
17 March	CN 12-2016	Chapter 9: Microbiology tests for donors and donations: general specifications for laboratory test procedures
2015		
	CN 30-2015	Chapter 7: Red Cells, Washed, Leucocyte Depleted
14 December		
14 December07 December	CN 18-2015	Chapter 7: Interruptions to agitation and testing of Platelets, Pooled, Buffy Coat Derived, Leucocyte Depleted and Platelets, Apheresis, Leucocyte Depleted

07 December	CN 20-2015	Chapter 6: Specific gravity of blood components
07 December	CN 21-2015	Chapter 7: Leucocyte depletion of blood components - Concessionary release
07 December	CN 22-2015	Chapter 7: Concessionary Release Limits for Selected Components
07 December	CN 23-2015	Chapter 9: Removal of Chapter 9.4.2. and Figure 9.6
07 December	CN 29-2015	25.6: Table 25.5: Protocol 000001 – blood component dispatch information
21 January	CN 01-2015	25.6: Tables 25.4 and 25.5: Protocol 000001 – blood component dispatch information
2014		
09 May	CN 25-2014	Chapter 5, Appendix I: Points of care
2013		
31 December	CN 15-2013	Chapter 3, Appendix I: Extra-corporeal volume tables
31 December	CN 16-2013	 7.9.1: Platelets, Pooled, Buffy Coat Derived, Leucocyte Depleted 7.11.1: Platelets in Additive Solution and Plasma, Leucocyte Depleted 7.12.1: Platelets in Additive Solution, Leucocyte Depleted 9.5.3.1: Single-test system 12.11.2: Blood and blood components from group O donors with high titres of anti-A, anti-B and/or anti-A,B
31 December	CN 17-2013	 7.15: Fresh Frozen Plasma, Leucocyte Depleted 7.16: Fresh Frozen Plasma, Methylene Blue Treated and Removed, Leucocyte Depleted 7.17: Cryoprecipitate, Leucocyte Depleted 7.18: Cryoprecipitate Pooled, Leucocyte Depleted 7.20: Plasma, Cryoprecipitate Depleted, Leucocyte Depleted 7.27: Fresh Frozen Plasma, Neonatal Use, Methylene Blue Treated and Removed, Leucocyte Depleted 7.28: Cryoprecipitate, Methylene Blue Treated and Removed, Leucocyte Depleted 7.33: Cryoprecipitate, Pooled, Methylene Blue Treated and Removed, Leucocyte Depleted
26 June	CN 11-2013	7.33: Cryoprecipitate, Pooled, Methylene Blue Treated and Removed, Leucocyte Depleted
26 June	CN 12-2013	Annexe 3: Platelets in Additive Solution and Plasma, Leucocyte Depleted, Pathogen-reduced